Positron emission tomography‐adapted therapy in low‐risk diffuse large B‐cell lymphoma: results of a randomized, phase III, non‐inferiority trial

BACKGROUND: The current standard of care for non‐bulky diffuse large B‐cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) but whether the same efficacy can be achieved wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Qing, He, Yang, Yi, Hong‐Mei, Mu, Rong‐Ji, Jiang, Xu‐Feng, Fu, Di, Dong, Lei, Qin, Wei, Xu, Peng‐Peng, Cheng, Shu, Song, Qi, Chen, Sai‐Juan, Wang, Li, Zhao, Wei‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397561/
https://www.ncbi.nlm.nih.gov/pubmed/37403255
http://dx.doi.org/10.1002/cac2.12462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397561/
https://www.ncbi.nlm.nih.gov/pubmed/37403255
http://dx.doi.org/10.1002/cac2.12462

Ejemplares similares